Classifications: hormone; human chorionic gonadotropin (hcg); Therapeutic:hcg hormone
Pregnancy Category: X
10,000 unit vial
Human chorionic gonadotropin (HCG) is a polypeptide hormone produced by the placenta and extracted from urine during first
trimester of pregnancy. Actions nearly identical to those of pituitary luteinizing hormone (LH). Promotes production of gonadal
steroid hormones by stimulating interstitial cells of the testes to produce androgen, and the corpus luteum of the ovary
to produce progesterone.
Administration of HCG to women of childbearing age with normal functioning ovaries causes maturation of the ovarian follicle
and triggers ovulation. When given during normal pregnancy, it maintains corpus luteum after LH decreases, supports continuing
secretion of estrogen and progesterone, and prevents ovulation.
Prepubertal cryptorchidism not due to anatomic obstruction and male hypogonadism secondary to pituitary deficiency. Also
used in conjunction with menotropins to induce ovulation and pregnancy in infertile women in whom the cause of anovulation
is secondary; ovulation usually occurs within 18 h. To stimulate spermatogenesis in males with hypogonadism.
Corpus luteum dysfunction.
Known hypersensitivity to HCG, hypogonadism of testicular origin, hamster protein hypersensitivity; hypertrophy or tumor
of pituitary, prostatic carcinoma or other androgen-dependent neoplasms, precocious puberty; ovarian failure; dysfunctional
uterine bleeding; adrenal insufficiency; uncontrolled thyroid disease; children <4 y; neonates; pregnancy (category X).
Epilepsy, migraine, asthma, cardiac or renal disease; endometriosis; thrombophlebitis; lactation.
Route & Dosage
Child: IM 4000 units 3 times/wk for 3 wk, or 5000 units q.o.d. for 4 doses, or 5001000 units 3 times/wk for 46 wk
Adult: IM 5001000 units 3 times/wk for 3 wk, then 2 times/wk for 3 wk or 4000 units 3 times/wk for 69 mo followed by 2000 units 3 times/wk for 3 mo
Stimulation of Spermatogenesis
Adult: IM 5000 units 3 times/wk until normal testosterone levels are achieved (46 mo), then 2000 units 2 times/wk with menotropins
for 4 mo
Induction of Ovulation
Adult: IM 5001000 units 1 d following last dose of menotropins
- Reconstitute only with diluent supplied by manufacturer.
- Following reconstitution solution is stable for 3090 d, depending on manufacturer, when refrigerated; thereafter potency
- Store powder for injection at 15°30° C (59°86° F) unless otherwise directed.
Adverse Effects (≥1%) Body as a Whole:
Edema, pain at injection site, arterial thromboembolism. Endocrine:
Gynecomastia, precocious puberty, increased urinary steroid excretion, ectopic pregnancy (incidence low). When used with
menotropins (human menopausal gonadotropin): Ovarian hyperstimulation (ascites with or without pain, pleural effusion, ruptured
ovarian cysts with resultant hemoperitoneum, multiple births). CNS:
Headache, irritability, restlessness, depression
Diagnostic Test Interference
Pregnancy tests: Possibility of false results.
No clinically significant drug interactions established. Herbal: Black cohosh
may antagonize fertility effects.
2 h. Peak:
6 h. Distribution:
Testes in males, ovaries in females. Elimination:
1012% in urine within 24 h. Half-Life:
Assessment & Drug Effects
- Assess prepubescent males for development of secondary sex characteristics.
- Assess females for and report excessive menstrual bleeding, irregular menstrual cycles, and abdominal/pelvic distention
Patient & Family Education
- Treatment for prepubertal cryptorchidism is usually started between 4 and 9 y. HCG can help predict whether orchidopexy
will be needed in the future.
- When used for treatment of infertility, timing of coitus is important. Daily intercourse is encouraged from day before HCG
is given until ovulation occurs.
- Report promptly onset of abdominal pain and distension (ovarian hyperstimulation syndrome).
- Report to physician if the following appear: axillary, facial, pubic hair; penile growth; acne; deepening of voice. Induction
of androgen secretion by HCG may induce precocious puberty in patient treated for cryptorchidism.
- Observe for signs of fluid retention. A weight chart should be maintained for a biweekly record. Report to physician if weight
gain is associated with edema.
- Report vaginal bleeding during treatment of corpus luteum deficiency; drug will be discontinued.